Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.1M
1M shares
52-week range
$2.44 – $32.55
15% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
www.autonomix.comNo one on the platform currently holds AMIX.
No tracked institution reports a position in AMIX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-06-24 | 1-for-21reverse |
| 2024-10-25 | 1-for-20reverse |
No one on the platform has traded AMIX yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$AMIX Hopefully will get back to $8 tomorrow morning.
View on StockTwits ↗$AMIX to the geniuses saying its going to 3 or 2. When it was at that level last time you said it was going to 1. I bought in the 2s, made multibagger although exited too early. I bought now at 50 d MA, Company has enough cash to get into 2027 and should soon file for FDA approval to run pivotal trial on their device.
View on StockTwits ↗$AMIX Warrant buyers who got in at $5.75 are selling in large numbers. As soon as the stock reaches $5.75, they’ll have sold out and will simply wait for the next stock offering at around $2. And that’s how the stock keeps getting diluted. This company has absolutely nothing in the pipeline—just debt and a constant need for cash. The only way they seem to get that cash is by issuing more shares and diluting existing shareholders over and over again, until eventually there’s hardly anything left.
View on StockTwits ↗$AMIX Is this sh-t ever be able to bottomed at any fckn fix price so people can start buying???? Seems like all these low life mfs messing up only .
View on StockTwits ↗$AMIX Revisiting $2.50 soon. Then another dilution at $1. The company is in desperate need of cash. No revenue, just cash burn and a going-concern warning. It will take years to turn this around, and by then the shares you're buying today could be worth $0.01.
View on StockTwits ↗$AMIX I hope all these low life parasites are out so Professionals can buy again and take it back on track .
View on StockTwits ↗$AMIX Warrants/future dilution, an enormous cash burn and the fact that the stock was trading at just $2.50 not long ago. None of that helps, despite the positive developments.
View on StockTwits ↗$AMIX Come on guys , this need to be $10 today after that big achievement. FDA approval is imminent now .
View on StockTwits ↗$AMIX today's news of completing the good lab practice study will enable them to apply to the FDA to begin the final study. The news is huge but history shows the stock is manipulated to only go up right before an offering.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $0 | — | $-22.68 | $-22.68–$-22.68 | — | 1 |
| 2028 | $900000 | — | $-19.53 | $-19.53–$-19.53 | — | 1 |
| 2029 | $2M | +94.4% | $-17.43 | $-17.43–$-17.43 | — | 1 |
| 2030 | $12M | +564.0% | $-12.39 | $-12.39–$-12.39 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $-6.40 | $-5.02 | +21.6% |
| 2026-06-04 | $-4.83 | $-4.83 | +0.0% |
| 2026-02-11 | $-0.36 | $-0.36 | +0.0% |
| 2025-11-12 | $-1.50 | $-1.38 | +8.0% |
| 2025-08-13 | $-0.89 | $-1.07 | -20.9% |
| 2025-05-29 | $-1.24 | $-1.83 | -48.6% |
| 2025-02-13 | $-1.46 | $-1.46 | +0.0% |
| $4M |
| — |
| HSCSHeartSciences Inc. | $2.06 | +3.00% | $4M | — |
| KALAKALA BIO, Inc. | $0.92 | +4.52% | $18M | — |
Source: Financial Modeling Prep · peers by sector/industry